tetano
Editor, Senior Moderator
Vaccine
. 2023 Oct 8:S0264-410X(23)01176-3.
doi: 10.1016/j.vaccine.2023.10.006. Online ahead of print. Safety, immunogenicity and efficacy of Relcovax®, a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus
Nikhil Sathe[SUP] 1 [/SUP], Sameer Shaikh[SUP] 1 [/SUP], Mahesh Bhavsar[SUP] 1 [/SUP], Leena Parte[SUP] 1 [/SUP], Anjaneyulu Gadiparthi[SUP] 1 [/SUP], Satish Kad[SUP] 1 [/SUP], Sayandev Sensarma[SUP] 1 [/SUP], Hassan Nalband[SUP] 1 [/SUP], R Sangapillai[SUP] 1 [/SUP], S Sivashanmuganathan[SUP] 1 [/SUP], Rakhi Pusalkar[SUP] 1 [/SUP], Sathyavathy Anandan[SUP] 1 [/SUP], Girish Masand[SUP] 1 [/SUP], K Pratapreddy[SUP] 1 [/SUP], S Harinarayana Rao[SUP] 1 [/SUP], Abhiram Gokhale[SUP] 1 [/SUP], G E C Vidyadhar Reddy[SUP] 1 [/SUP], Gopala Karanam[SUP] 1 [/SUP], Abhishek Phatarphekar[SUP] 1 [/SUP], Praveen Rao[SUP] 1 [/SUP], Venkata Ramana[SUP] 1 [/SUP], R L Ramnath[SUP] 2 [/SUP]
Affiliations
SARS-CoV-2, severe acute respiratory syndrome coronavirus-2, causes coronavirus disease- 2019 (COVID-19). Mostly, COVID-19 causes respiratory symptoms that can resemble those of a cold, the flu, or pneumonia. COVID-19 may harm more than just lungs and respiratory systems. It may also have an impact on other parts of the body and debilitating effects on humans, necessitating the development of vaccines at an unprecedented rate in order to protect humans from infections. In response to SARS-CoV-2 infection, mRNA, viral vector-based carrier and inactivated virus-based vaccines, as well as subunit vaccines, have recently been developed. We developed Relcovax®, a dual antigen (Receptor binding domain (RBD) and Nucleocapsid (N) proteins) subunit protein vaccine candidate. Preliminary mouse preclinical studies revealed that Relcovax® stimulates cell-mediated immunity and provides broader protection against two SARS-CoV-2 variants, including the delta strain. Before conducting human studies, detailed preclinical safety assessments are required, so Relcovax® was tested for safety, and immunogenicity in 28-day repeated dose toxicity studies in rats and rabbits. In the toxicity studies, there were no mortality or morbidity, abnormal clinical signs, abnormalities in a battery of neurobehavioral observations, abnormalities in detailed clinical and ophthalmological examinations, or changes in body weights or feed consumption. In any of the studies, no abnormal changes in organ weights, haematology, clinical chemistry, urinalysis parameters, or pathological findings were observed. Immunogenicity tests on rats and rabbits revealed 100 % seroconversion. Relcovax® was therefore found to be safe in animals, with a No Observed Adverse Effect Level (NOAEL) of 20 µg/protein in rats and rabbits. In efficacy studies, Relcovax® immunised hamsters demonstrated dose-dependent protection against SARS-CoV-2 infection, with a high dose (20 µg/protein) being the most protective, while in cynomolgus macaque monkey study, lowest dose 5 µg/protein had the highest efficacy. In conclusion, Relcovax® was found to be safe, immunogenic, and efficacious in in vivo studies.
Keywords: Covid-19; Cynomolgus macaque monkey; Efficacy; Immunogenicity; Rabbit and hamsters; Rat; SARS-CoV-2; Safety.
. 2023 Oct 8:S0264-410X(23)01176-3.
doi: 10.1016/j.vaccine.2023.10.006. Online ahead of print. Safety, immunogenicity and efficacy of Relcovax®, a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus
Nikhil Sathe[SUP] 1 [/SUP], Sameer Shaikh[SUP] 1 [/SUP], Mahesh Bhavsar[SUP] 1 [/SUP], Leena Parte[SUP] 1 [/SUP], Anjaneyulu Gadiparthi[SUP] 1 [/SUP], Satish Kad[SUP] 1 [/SUP], Sayandev Sensarma[SUP] 1 [/SUP], Hassan Nalband[SUP] 1 [/SUP], R Sangapillai[SUP] 1 [/SUP], S Sivashanmuganathan[SUP] 1 [/SUP], Rakhi Pusalkar[SUP] 1 [/SUP], Sathyavathy Anandan[SUP] 1 [/SUP], Girish Masand[SUP] 1 [/SUP], K Pratapreddy[SUP] 1 [/SUP], S Harinarayana Rao[SUP] 1 [/SUP], Abhiram Gokhale[SUP] 1 [/SUP], G E C Vidyadhar Reddy[SUP] 1 [/SUP], Gopala Karanam[SUP] 1 [/SUP], Abhishek Phatarphekar[SUP] 1 [/SUP], Praveen Rao[SUP] 1 [/SUP], Venkata Ramana[SUP] 1 [/SUP], R L Ramnath[SUP] 2 [/SUP]
Affiliations
- PMID: 37816655
- DOI: 10.1016/j.vaccine.2023.10.006
SARS-CoV-2, severe acute respiratory syndrome coronavirus-2, causes coronavirus disease- 2019 (COVID-19). Mostly, COVID-19 causes respiratory symptoms that can resemble those of a cold, the flu, or pneumonia. COVID-19 may harm more than just lungs and respiratory systems. It may also have an impact on other parts of the body and debilitating effects on humans, necessitating the development of vaccines at an unprecedented rate in order to protect humans from infections. In response to SARS-CoV-2 infection, mRNA, viral vector-based carrier and inactivated virus-based vaccines, as well as subunit vaccines, have recently been developed. We developed Relcovax®, a dual antigen (Receptor binding domain (RBD) and Nucleocapsid (N) proteins) subunit protein vaccine candidate. Preliminary mouse preclinical studies revealed that Relcovax® stimulates cell-mediated immunity and provides broader protection against two SARS-CoV-2 variants, including the delta strain. Before conducting human studies, detailed preclinical safety assessments are required, so Relcovax® was tested for safety, and immunogenicity in 28-day repeated dose toxicity studies in rats and rabbits. In the toxicity studies, there were no mortality or morbidity, abnormal clinical signs, abnormalities in a battery of neurobehavioral observations, abnormalities in detailed clinical and ophthalmological examinations, or changes in body weights or feed consumption. In any of the studies, no abnormal changes in organ weights, haematology, clinical chemistry, urinalysis parameters, or pathological findings were observed. Immunogenicity tests on rats and rabbits revealed 100 % seroconversion. Relcovax® was therefore found to be safe in animals, with a No Observed Adverse Effect Level (NOAEL) of 20 µg/protein in rats and rabbits. In efficacy studies, Relcovax® immunised hamsters demonstrated dose-dependent protection against SARS-CoV-2 infection, with a high dose (20 µg/protein) being the most protective, while in cynomolgus macaque monkey study, lowest dose 5 µg/protein had the highest efficacy. In conclusion, Relcovax® was found to be safe, immunogenic, and efficacious in in vivo studies.
Keywords: Covid-19; Cynomolgus macaque monkey; Efficacy; Immunogenicity; Rabbit and hamsters; Rat; SARS-CoV-2; Safety.